Anti-cancer agent sensitivity-determining marker
AssigneesKeio University, Kabushiki Kaisha Yakult Honsha
InventorsYusuke TANIGAWARA, Kanako HARA, Miki NAKAMURA, Shinji SUGIMOTO, Hiroyuki TAKAHASHI
Life of this patent
Estimating the term…
Abstract
A novel marker for determining sensitivity to an anti-cancer agent is provided. Disclosed is a marker for determining sensitivity to an anti-cancer agent including one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1 and COX5A.
Claims16
A marker for determining sensitivity to an anti-cancer agent, comprising
- one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1, and COX5A.
A method for determining sensitivity to an anti-cancer agent, the method comprising a step of measuring amounts of one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1, and COX5A in a biological sample derived from a cancer patient.
A screening method for an anti-cancer agent sensitivity enhancer, the method comprising employing, as an index, variation in expression of one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1 and COX5A in a cancer cell line or a biological sample derived from a tumor-bearing animal in the presence of an anti-cancer agent.
Dependencies are inferred from the claim text.